Trial Profile
Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma; Plasma cell leukaemia; Plasmacytoma
- Focus Therapeutic Use
- 24 Apr 2023 Planned End Date changed from 15 Dec 2022 to 15 Jun 2023.
- 19 May 2022 Planned End Date changed from 15 Dec 2021 to 15 Dec 2022.
- 08 Jan 2021 Planned End Date changed from 15 Dec 2020 to 15 Dec 2021.